Date Posted:08:03:02 11/06/03 Thu Author: Brenda Author Host/IP: netcache-3001.bay.webtv.net / 209.240.205.60 Subject: Clinical Research of ß endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis/This is only the Abstract link
I am not a paying member of the Journal of Neurology Neurosurgery and Psychiatry.
ß endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis
M Gironi1, R Furlan1, M Rovaris1, G Comi1, M Filippi1, A E Panerai2 and P Sacerdote2
1 Department of Neuroscience, San Raffaele Hospital, Milan, Italy
2 Department of Pharmacology, University of Milan, Milan, Italy
Correspondence to:
Dr M Gironi, San Raffaele, DIMER, Via Olgettina 48, 20132, Milan, Italy;
mgironi@dongnocchi.it
ABSTRACT
The possible link between the opioid peptide ß endorphin and the heterogeneity of the clinical course of multiple sclerosis (MS) was investigated. Peripheral blood mononuclear cells (PBMC) concentrations of ß endorphin were measured in 50 patients in different phases of MS. Thirty nine patients also underwent post-contrast magnetic resonance imaging of the brain. Among MS forms, the highest ß endorphin concentrations were found in PBMC from patients with relapsing remitting MS and the lowest in patients with the progressive forms. Average ß endorphin concentrations were lower, although not significantly, in patients with than in those without magnetic resonance imaging enhanced lesions. These data suggest that ß endorphin may have a role in the downregulation of the inflammatory process.